替格瑞洛对急性冠脉综合征患者EMPs和sICAM-1的影响及预后观察

Abstract
Figure/Table
References (21)
Related Citation (6)

Download: PDF (400 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the changes of serum endothelial microparticles (EMPs) and soluble intercellular adhesion molecule-1 (sICAM-1) levels and prognosis of Ticagrelor in treatment of patients with Non-ST-Elevation acute coronary syndrome (NSTE-ACS). Methods A total of 146 patients with NSTE-ACS admitted to the Third Affiliated Hospital of Guangzhou Medical University from January to June 2019, according to the random number table method, patients were divided into two groups, with 73 patients in each group. Clopidogrel group was treated with Clopidogrel, Ticagrelor group was treated with Ticagrelor. The levels of EMPs and sICAM-1 in the two groups were observed before percutaneous coronary intervention (PCI) as well as 24 h, 7 d and 30 d after PCI. The major adverse cardiac events (MACE) and adverse reactions were compared between the two groups within six months after PCI. Results The levels of EMPs and sICAM-1 of the two groups increased significantly at 24 h after PCI, decreased significantly at seven days after PCI compared with 24 h after PCI, and decreased significantly at 30 d after PCI compared with seven days after PCI, the differences were statistically significant (P ＜ 0.05). The levels of EMPs and sICAM-1 in Ticagrelor group were lower than those in Clopidogrel group seven days after PCI, and were lower than those in Clopidogrel group 30 d after PCI， and the differences were statistically significant (P ＜ 0.05). The total MACE events in Ticagrelor group were lower than that in Clopidogrel group, the differences were statistically significant (P ＜ 0.05), and there was no statistical difference in the incidence of bleeding events between the two groups (P ＞ 0.05). Conclusion Ticagrelor can improve endothelial function and reduce inflammatory reaction more rapidly in the treatment of NSTE-ACS patients, andstabilize atherosclerotic plaques, protect myocardium and does not increase bleeding risk.

Key words： Ticagrelor Non-ST-Elevation acute coronary syndrome Endothelial microparticles Soluble intercellular adhesion molecule-1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	TAN Wenpeng LI Wenjie HE Xiaoqing

Cite this article:

TAN Wenpeng LI Wenjie HE Xiaoqing. Effects of Ticagrelor on EMPs and sICAM-1 in patients with acute coronary syndrome and its prognosis[J]. 中国医药导报, 2020, 17(30): 142-145.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I30/142

[1] Hedayati T，Yadav N，Khanagavi J. Non-ST-Segment Acute Coronary Syndromes [J]. Cardiol Clin，2018，36（1）：37-52.
[2] Morici N，Savonitto S，Ferri LA，et al. Outcomes of Elderly Patients with ST-Elevation or Non-ST-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention [J]. Am J Med，2019，132（2）：209-216.
[3] Gorog DA，Geisler T. Platelet Inhibition in Acute Coronary Syndrome and Percutaneous Coronary Intervention：Insights from the Past and Present [J]. Thromb Haemost，2020.
[4] Brener SJ，Alapati V，Benson MM，et al. Ticagrelor vs Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention：Insights From a Single Institution Registry [J]. J Invasive Cardiol，2019，31（8）：235-238.
[5] Guan W，Lu H，Yang K. Choosing between ticagrelor and clopidogrel following percutaneous coronary intervention：A systematic review and Meta-Analysis （2007-2017）[J]. Medicine （Baltimore），2018，97（43）：e12978.
[6] Ow KW，Wae P，Porter MM，et al. Offset of ticagrelor prior to coronary artery bypass graft surgery for acute coronary syndromes：effects on platelet function and cellular adenosine uptake [J]. Platelets，2020：1-7.
[7] Gunay M，Mertoglu C. Increase of endocan，a new marker for inflammation and endothelial dysfunction，in acute kidney injury [J]. North Clin Istanb，2019，6（2）：124-128.
[8] 中华医学会心血管病学分会，中华心血管病杂志编辑委员会.非ST段抬高型急性冠状动脉综合征诊断和治疗指南（2016）[J].中华心血管病杂志，2017，45（5）：359-376.
[9] Wang D，Yang XH，Zhang JD，et al. Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome：a meta-analysis [J]. BMC Cardiovasc Disord，2018，18（1）：217.
[10] Tun?觭ez A，Altunkeser BB，?魻ztürk B，et al. Comparative effects of atorvastatin 80 mg and rosuvastatin 40 mg on the levels of serum endocan，chemerin，and galectin-3 in patients with acute myocardial infarction [J]. Anatol J Cardiol，2019，22（5）：240-249.
[11] Benameur T，Osman A，Parray A，et al. Molecular Mechanisms Underpinning Microparticle-Mediated Cellular Injury in Cardiovascular Complications Associated with Diabetes [J]. Oxid Med Cell Longev，2019，2019：6475187.
[12] Kosir G，Jug B，Novakovic M，et al. Endocan Is an Independent Predictor of Heart Failure-Related Mortality and Hospitalizations in Patients with Chronic Stable Heart Failure [J]. Dis Markers，2019，2019：9134096.
[13] Zarà M，Guidetti GF，Camera M，et al. Biology and Role of Extracellular Vesicles （EVs） in the Pathogenesis of Thrombosis [J]. Int J Mol Sci，2019，20（11）：2840.
[14] Zhang Q，Shang M，Zhang M，et al. Microvesicles derived from hypoxia/reoxygenation-treated human umbilical vein endothelial cells promote apoptosis and oxidative stress in H9c2 cardiomyocytes [J]. BMC Cell Biol，2016，17（1）：25.
[15] Gan L，Xie D，Liu J，et al. Small Extracellular Microvesicles Mediated Pathological Communications between Dysfunctional Adipocytes and Cardiomyocytes as a Novel Mechanisms Exacerbating Ischemia/Reperfusion Injury in Diabetic Mice [J]. Circulation，2020，141（12）：968-983.
[16] Wang B，Li T，Han X，et al. The Level of Circulating Microparticles in Patients with Coronary Heart Disease：a Systematic Review and Meta-Analysis [J]. J Cardiovasc Transl Res，2020，13（5）：702-712.
[17] Anbarasan C，Bavanilatha M，Latchumanadhas K，et al. ICAM-1 molecular mechanism and genome wide SNP's association studies [J]. Indian Heart J，2015，67（3）：282-287.
[18] Tishko VV，Sokolov AA，Belskih AN，et al. Impact of double filtration plasmapheresis on adhesion molecules levels in patients with stable coronary heart disease after coronary stenting [J]. Atheroscler Suppl，2017，30：92-98.
[19] Ma CY，Xu ZY，Wang SP，et al. Change of Inflammatory Factors in Patients with Acute Coronary Syndrome [J]. Chin Med J（Engl），2018，131（12）：1444-1449.
[20] Hu P，Dai T，Yu W，et al. Intercellular adhesion molecule 1 rs5498 polymorphism is associated with the risk of myocardial infarction [J]. Oncotarget，2017，8（32）：52594-52603.
[21] Doc L，Freitas IA，Meneses GC，et al. Interleukin-6 and adhesion molecules VCAM-1 and ICAM-1 as biomarkers of post-acute myocardial infarction heart failure [J]. Braz J Med Biol Res，2019，52（12）：e8658.